Clinical Trials Logo

Esophagogastric Adenocarcinoma clinical trials

View clinical trials related to Esophagogastric Adenocarcinoma.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03921021 Completed - Clinical trials for Esophagogastric Adenocarcinoma

Phase 2 Study of Telomelysin (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma

Start date: May 9, 2019
Phase: Phase 2
Study type: Interventional

This is a phase II study of OBP-301 with pembrolizumab in advanced gastric and gastroesophageal junction adenocarcinoma that has progressed on at least 2 lines of prior therapy for advanced disease.

NCT ID: NCT03193918 Completed - Clinical trials for Esophagogastric Adenocarcinoma

Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma

Start date: April 14, 2017
Phase: Phase 1
Study type: Interventional

This is a single-arm phase I/Ib study of crenolanib combined with ramucirumab/paclitaxel as second line therapy for patients with advanced/metastatic adenocarcinoma of the esophagus, GEJ or stomach. Patients will be enrolled in two phases; dose escalation phase and dose expansion phase.

NCT ID: NCT02234596 Completed - Clinical trials for Esophagogastric Adenocarcinoma

Nintedanib in Patients With Advanced Esophagogastric Cancer

Start date: September 4, 2014
Phase: Phase 2
Study type: Interventional

This is a phase II study of Nintedanib in patients with metastatic or recurrent esophagogastric cancer. The goal of the study is to evaluate the efficacy of Nintedanib, an orally available triple kinase inhibitor targeting the receptors of the vascular endothelial growth factor (VEGF), platelet derived growth factor (PDGF), and fibroblast growth factor (FGF) receptor pathways.